EVALUATING THE COST-EFFECTIVENESS OF ONCE-WEEKLY SEMAGLUTIDE 1 MG VERSUS EMPAGLIFLOZIN 25 MG FOR TREATMENT OF PATIENTS WITH TYPE 2 DIABETES IN THE UK SETTING

被引：0
|
作者：
Capehorn, M. [1 ]
Hallen, N. [2 ]
Hunt, B. [3 ]
机构：
[1] Rotherham Inst Obes, Rotherham, S Yorkshire, England
[2] Novo Nordisk AS, Soborg, Denmark
[3] Ossian Hlth Econ & Commun, Basel, Switzerland
来源：
VALUE IN HEALTH | 2020年 / 23卷
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PDB42
引用
收藏
页码：S512 / S512
页数：1
相关论文
共 50 条
  • [1] Evaluating the Cost-Effectiveness of Once-Weekly Semaglutide 1 mg Versus Empagliflozin 25 mg for Treatment of Patients with Type 2 Diabetes in the UK Setting
    Capehorn, Matthew
    Hallen, Nino
    Baker-Knight, James
    Glah, Divina
    Hunt, Barnaby
    DIABETES THERAPY, 2021, 12 (02) : 537 - 555
  • [2] Evaluating the Cost-Effectiveness of Once-Weekly Semaglutide 1 mg Versus Empagliflozin 25 mg for Treatment of Patients with Type 2 Diabetes in the UK Setting
    Matthew Capehorn
    Nino Hallén
    James Baker-Knight
    Divina Glah
    Barnaby Hunt
    Diabetes Therapy, 2021, 12 : 537 - 555
  • [3] Cost-Effectiveness of Once-Weekly Semaglutide 1 mg versus Canagliflozin 300 mg in Patients with Type 2 Diabetes Mellitus in a Canadian Setting
    Sara Stafford
    Peter G. Bech
    Adam Fridhammar
    Nino Miresashvili
    Andreas Nilsson
    Michael Willis
    Aiden Liu
    Applied Health Economics and Health Policy, 2022, 20 : 543 - 555
  • [4] Cost-Effectiveness of Once-Weekly Semaglutide 1 mg versus Canagliflozin 300 mg in Patients with Type 2 Diabetes Mellitus in a Canadian Setting
    Stafford, Sara
    Bech, Peter G.
    Fridhammar, Adam
    Miresashvili, Nino
    Nilsson, Andreas
    Willis, Michael
    Liu, Aiden
    APPLIED HEALTH ECONOMICS AND HEALTH POLICY, 2022, 20 (04) : 543 - 555
  • [5] Correction to: Cost-Effectiveness of Once-Weekly Semaglutide 1 mg versus Canaglifozin 300 mg in Patients with Type 2 Diabetes Mellitus in a Canadian Setting
    Sara Stafford
    Peter G. Bech
    Adam Fridhammar
    Nino Miresashvili
    Andreas Nilsson
    Michael Willis
    Aiden Liu
    Applied Health Economics and Health Policy, 2022, 20 : 623 - 623
  • [6] A Long-term Cost-Effectiveness Analysis of Treatments for Type 2 Diabetes in Portugal: Once-Weekly Semaglutide 1 mg Versus Once-Daily Empagliflozin 25 mg
    Carvalho, Davide
    Costa, Catarina
    Hallen, Nino
    Baker-Knight, James
    Hunt, Barnaby
    REVISTA PORTUGUESA DE ENDOCRINOLOGIA DIABETES E METABOLISMO, 2021, 16 (1-2) : 13 - 20
  • [7] A LONG-TERM COST-EFFECTIVENESS ANALYSIS OF TREATMENTS FOR TYPE 2 DIABETES IN PORTUGAL: ONCE-WEEKLY SEMAGLUTIDE 1 MG VERSUS ONCE-DAILY EMPAGLIFLOZIN 25 MG
    Hallen, N.
    Carvalho, D.
    Costa, C.
    Hunt, B.
    VALUE IN HEALTH, 2020, 23 : S510 - S510
  • [8] COST-EFFECTIVENESS OF ONCE-WEEKLY SEMAGLUTIDE 1 MG VS. CANAGLIFLOZIN 300 MG IN PATIENTS WITH TYPE 2 DIABETES IN A CANADIAN SETTING
    Liu, A.
    Bech, P.
    Fridhammar, A.
    Nilsson, A.
    Willis, M.
    Johansen, P.
    VALUE IN HEALTH, 2020, 23 : S114 - S114
  • [9] LONG-TERM COST-EFFECTIVENESS ANALYSES OF ONCE-WEEKLY SEMAGLUTIDE 1 MG VERSUS EMPAGLIFLOZIN 25 MG FOR TREATMENT OF TYPE 2 DIABETES IN THREE COUNTRIES: BOSNIA AND HERZEGOVINA, GREECE, AND SLOVENIA
    Hallen, N.
    Djekic, D.
    Ioannidis, I.
    Liatis, S.
    Lapajne, Ogric A.
    Thanopoulou, A.
    Hunt, B.
    VALUE IN HEALTH, 2020, 23 : S511 - S511
  • [10] Evaluating the Long-Term Cost-Effectiveness of Once-Weekly Semaglutide 1 mg Versus Liraglutide 1.8 mg: A Health Economic Analysis in the UK
    Marc Evans
    Sasha Berry
    Samuel J. P. Malkin
    Barnaby Hunt
    Abheet Sharma
    Diabetes Therapy, 2023, 14 : 1005 - 1021
12345